Announced details
Treatment of stiff shoulders, neck pain and other conditions
The Daito Group's sixth proprietary generic drug in China
大桐製薬（中国）有限責任公司, a consolidated subsidiary of Daito Pharmaceutical Co.,Ltd., obtained the approval. The active pharmaceutical ingredient is scheduled to be manufactured by the group company 安徽鼎旺医薬有限公司.
China's pharmaceutical regulatory authority
大桐製薬（中国）有限責任公司: Hefei, Anhui, China / 安徽鼎旺医薬有限公司: Anqing, Anhui, China
The impact has already been incorporated into the earnings forecast, and there is no revision to the consolidated earnings forecast.
The company does not address Contract Value / Offering price.
China's National Medical Products Administration (NMPA)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Eperisone Hydrochloride Tablets 50 mg (盐酸乙哌立松片 50mg) |
| Counterparty | China's National Medical Products Administration (NMPA) |
| Counterparty overview | China's pharmaceutical regulatory authority |
| Relationship with the Company | 大桐製薬（中国）有限責任公司, a consolidated subsidiary of Daito Pharmaceutical Co.,Ltd., obtained the approval. The active pharmaceutical ingredient is scheduled to be manufactured by the group company 安徽鼎旺医薬有限公司. |
| Applicable area | Treatment of stiff shoulders, neck pain and other conditions |
| Location | 大桐製薬（中国）有限責任公司: Hefei, Anhui, China / 安徽鼎旺医薬有限公司: Anqing, Anhui, China |
| Usage history | The Daito Group's sixth proprietary generic drug in China |
| Impact on Business Performance | The impact has already been incorporated into the earnings forecast, and there is no revision to the consolidated earnings forecast. |
| Source | China's National Medical Products Administration (NMPA) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In response to regulatory changes in China, the parties agreed that having 大桐製薬 hold the manufacturing and marketing rights would provide a competitive advantage in its sales strategy.